Sunday, September 22, 2019

CGLytics and Glass Lewis Set a New Standard for Transparency in Equity-based Compensation

 Newly released technology tests 11 key criteria that leading proxy advisor uses to assess plans

AMSTERDAM & LONDON & SAN FRANCISCO-Friday 20 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- CGLytics, a leading global provider of governance data and analytics, and Glass Lewis, the world’s leading independent provider of governance and engagement support services, today announced the launch of Glass Lewis’ Equity Compensation Model (ECM) - a powerful new application for assessing U.S. equity-based compensation plans, available exclusively via CGLytics.

This new application provides invaluable intelligence with year-round, on-demand access to Glass Lewis’ methodology which is used to evaluate the overall favorability of current and future equity plans, including tests against 11 key criteria. Companies and investors can now instantly test, review and adjust the same individual inputs as Glass Lewis’ analysts to ensure the best compensation, engagement and voting outcomes for their respective sides.

The ECM provides companies with immediate and proactive insight into the concerns regarding current and future equity plans, which Glass Lewis highlights to more than 1,300 investors representing more than $35 trillion in assets under management. In addition, with coverage of more than 4,300 publicly traded U.S. companies, investors can assess investment risks across their portfolio with regard to current equity plans or those being proposed.

Aaron Bertinetti, SVP of Research & Engagement at Glass Lewis explains: “Our analysts research and openly engage with thousands of companies and their investors every year, building invaluable insight and governance expertise as a result. We strongly believe that good governance is good for everybody, which means we must empower the capital markets by democratizing access to our deep governance expertise in a transparent, intuitive and unconflicted manner. The ECM gives companies and investors the same governance tools we use internally and have developed over many years. It will bring greater transparency, improved governance and market confidence by fostering alignment of corporate and investor interests in compensation plans.”

The ECM is available as a stand-alone service and is only available via CGLytics and its market-leading software. Corporate issuers can test and refine their equity plans, understand the level of concern from shareholders and ultimately be successful in seeking the shareholder support required to legally grant equity compensation. On the other hand, investors can test the equity plans for companies in their portfolio, perform comprehensive benchmarking of plan costs and evaluate the risk of any potential dilution to enhance their engagement and voting decisions.

“Getting equity compensation right is a pivotal part of modernizing corporate governance. Issuers and institutional investors must be satisfied that proposed plans meet the long-term needs for the business and its shareholders. ECM will completely change the way both sides approach these challenges, setting a new benchmark for transparency in the decision-making process and driving good governance practices.” said Aniel Mahabier, CEO of CGLytics.

The offering, initially launched for the U.S. market, covers 4,300+ publicly traded U.S. firms including the Russell 3000, S&P 1500, S&P MidCap 400 and SmallCap 600.

About CGLytics

CGLytics is transforming the way corporate governance decisions are made. Combining the broadest corporate governance dataset, with the most comprehensive analytics tools, CGLytics empowers corporations, investors and professional services to instantly perform a governance health check and make better informed decisions. From unique Pay for Performance analytics and peer comparison tools, to board effectiveness insights, companies and investors have access to the most comprehensive source of governance information at their fingertips – powering the insights required for good modern governance.

About Glass Lewis

Glass Lewis, the leading independent provider of global governance and engagement support services, helps institutional investors understand and connect with companies they invest in. Glass Lewis is a trusted ally of more than 1,300 investors globally who use its high-quality, unbiased Proxy Paper research and industry-leading Viewpoint proxy vote management solution to drive value across all their governance activities.

View source version on


Rob Alport, +44 2071474541

Permalink :

Visa B2B Connect Expands to 32 New Countries and Announces Integration With Infosys

Expansion will help financial institutions quickly and securely process global corporate cross-border payments

SAN FRANCISCO-Saturday 21 September 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Visa Inc. (NYSE:V) today announced that its Visa B2B Connect network has doubled its reach – from 30 global trade corridors at launch in June 2019, to 62, with the goal to expand to over 100 countries in 2020.

In addition, Infosys, a global leader in next-generation digital services and consulting, is integrating with the Visa B2B Connect network to bring Visa B2B Connect platform access to their participating financial institutions worldwide.

Through this new connection, participating financial institutions worldwide can take advantage of the ability to quickly and securely process corporate cross-border payments globally through Visa B2B Connect.1

“Visa B2B Connect is a fast, secure and more efficient network, designed specifically to overcome obstacles in the cross-border corporate payments space,” said Alan Koenigsberg, global head, new payment flows, Visa Business Solutions. “We are excited to bring on Infosys and expand Visa B2B Connect to new geographies – all in a joint effort to accelerate innovation and increase efficiencies for financial institutions and their corporate clients.”

In addition to Visa’s new collaboration with Infosys, participating clients can also connect to Visa B2B Connect through Bottomline and FIS, Visa’s previously-announced hub partners.

Participating clients can now connect to Visa B2B Connect via Bottomline’s Universal Aggregator. Joint customers can take advantage of Bottomline’s modern API connectivity to effortlessly access Visa B2B Connect, and begin transacting through their existing Bottomline connections, minimizing technology adjustments.

According to a recent survey commissioned by Visa2, almost six-in-ten respondents (59%) expect overall revenues from cross-border payments to increase in the next five years as a result of faster payments. Nearly a quarter of respondents (24%) expect to see faster payments drive up revenues by as much as 25%.

Visa B2B Connect helps remove friction and time spent on cross-border corporate payments by facilitating transactions from the bank of origin directly to the beneficiary bank. The network drastically increases visibility into the transaction flow, giving buyers and suppliers an opportunity to track the status of payments from the origin bank to the destination bank in near real time.

Visa B2B Connect can also significantly reduce the time to settle funds – from potentially weeks to one to two days. It gives corporate financial institutions and their customers a clear view of fees associated with a payment, helping companies better manage their cash flow. In order to begin transacting through Visa B2B Connect, participating financial institutions around the world can connect in two ways – directly to the network or through Visa’s hub partners.

Visa B2B Connect’s unique digital identity feature tokenizes an organization’s sensitive business information, such as banking details and account numbers, giving them a unique identifier that can be used to facilitate transactions on the network. Visa B2B Connect’s digital identity feature will transform the way information is exchanged in business-to-business cross-border transactions.

“Differentiated capabilities of Visa B2B Connect and our work with early adopters is truly set to transform the speed, security and profitability for the entire ecosystem,” added Koenigsberg.

Rob Eberle, CEO and president of Bottomline said, “We are delighted to be partnering with Visa on such an important initiative. The powerful combination of our technologies and continued commitment and investment in cross-border B2B payments innovation will help ensure banks can thrive and grow in the open and faster payments world.”

“Infosys is looking forward to partnering with Visa to create new payment flows for Commercial Payments,” said Narayan Sivaram (Nans), VP, global head, cards & payments, Infosys. “We believe that through this engagement we will be able to jointly reach a large number of banks and support their cross border needs.”

To learn more about Visa B2B Connect, please visit Visa at Sibos 2019, in London, September 23-26 at stand K123. Further information is available by accessing the Visa B2B Connect: Cross-Border Payments Reimagined paper, on or by contacting

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device, for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, and @VisaNews.

1 Availability varies by country

2 Survey commissioned by Visa Inc. and conducted among banks and corporates in 20 markets in June, 2019 by East & Partners.

View source version on


Aida Hadzibegovic

Permalink :

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

 Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement

The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics’ intravitreal drug delivery technology

Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization

INGELHEIM, Germany and NEWTON, Mass.-Friday 20 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.

“We are delighted to enter into a collaboration with a company of Boehringer Ingelheim’s stature,” said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. “We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development.”

“Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

Please click on the link for ´Notes to Editors´and ´References´:

View source version on


Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672

Inflammasome Therapeutics
Bev. Jedynak
Bevlyn Consulting
+1 312 943 1123
+1 773 350 5793

Permalink :

Rimini Street Wins Gold Stevie® Award for “Company of the Year – Computer Services” in both the 2019 American Business Awards and the 2019 International Business Awards

Company recognized for global growth and innovation, corporate social responsibility and delivering excellence in customer service

LAS VEGAS.-Saturday 21 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced it has been named a Gold Stevie® Award winner for Company of the Year – Computer Services in both the 2019 American Business Awards® (ABA) and the 2019 International Business Awards® (IBA). Rimini Street was also recognized with two additional Gold Stevie ABAs for Customer Service Team of the Year and Product Management Team of the Year.

Global Growth and Service Innovation

Rimini Street garnered the Gold Stevie award for Company of the Year – Computer Services in both the American and International Business award programs for its global growth and service innovation through 2018 including the expansion of its global workforce, new product and service offerings, the opening of new offices and facilities and the Company’s full year revenue growth.

Continuing to evolve and innovate its service and support offerings, the Company launched new products and services including its Application Management Services for Salesforce Sales Cloud and Service Cloud. Rimini Street also launched Rimini Street Mobility and Rimini Street Analytics solutions that cost-effectively modernize ERP systems without requiring expensive upgrades of the ERP software.

Delivering Excellence in Customer Support

Rimini Street’s Global Product Delivery team, responsible for providing thousands of tax, legal and regulatory (TLR) updates supporting millions of lines of code, was also awarded a Gold Stevie for Product Management Team of the Year. In its drive to continually improve upon its service and client satisfaction, the team transitioned from a Waterfall development process to leveraging an Agile framework, significantly improving overall efficiency and time to deliver updates. During 2018, the Global Product Delivery team provided more than 49,000 individual TLR updates to clients across 30 countries. Every update provided to a client is customized for their needs and environment.

Rimini Street’s Global Support team was also recognized with two Stevie awards for Customer Service Department of the Year, and the Company’s group vice president of Global Support, Craig Mackereth, was honored with two Stevie awards for Customer Service Executive of the Year.

In addition to the numerous award wins presented to Rimini Street’s Global Service Delivery team for delivering excellence in customer service to its clients externally, Rimini Street’s internal IT Department was recognized, winning IT Department of the Year for the team’s focus on excellence, value, and reliability, and for being a trusted partner and advisor to the Company’s global employees.

Corporate Social Responsibility Program of the Year Award

The Rimini Street Foundation was also recognized with an award, receiving a Stevie ABA for Corporate Social Responsibility Program of the Year for its “The More We Grow, the More We Can Give” program. The Foundation was launched as a reflection of the values, hearts and passion of Rimini Street and its employees. As the Company grows, it enables the Foundation to invest back into the communities where Rimini Street employees live. In 2018, Rimini Street partnered with 56 charities around the world, providing financial contributions, in-kind donations and more than 1,200 employee volunteer hours with organizations such as the Boys & Girls Club of Oakland, Balavikas School in Hyderabad, India, and Casa José Eduardo Cavichio House in Brazil.

“We are honored to be recognized by the Stevie Awards for Rimini Street’s excellent client service, our industry-leading enterprise software support model, continued company growth, and the important community work of the Rimini Street Foundation,” said Seth A. Ravin, Rimini Street CEO. “These awards recognize the high quality, ultra-responsive service we deliver to nearly 1,900 clients globally as we continuously improve and innovate our service delivery model and expand our support offerings and operations.”

About The Stevie Awards

Stevie Awards are conferred in seven programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. Nearly 1,900 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries rely on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (C-RMNI)

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation (including our pending appeal of the permanent injunction) or in the government inquiry or any new litigation; the final amount and timing of any refunds from Oracle related to our litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the terms and impact of our outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services, Rimini Street Mobility, Rimini Street Analytics, Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 8, 2019, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2019 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

View source version on


Michelle McGlocklin
Rimini Street, Inc.
+1 925 523-8414

Permalink :

Saturday, September 21, 2019

Patient Safety Leaders and Advocates Discuss Solutions to Eliminate Preventable Patient Deaths

 Stakeholders meet at Patient Safety Movement Foundation Midyear Planning meeting to plan for ZERO preventable deaths in hospitals

IRVINE, Calif. -Friday 20 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- On the same day the World Health Organization (WHO) designated World Patient Safety Day, The Patient Safety Movement Foundation’s (PSMF) Midyear Planning Meeting (MYPM) brought together more than a hundred patient safety stakeholders from across seven countries for intimate discussions about how to achieve ZERO preventable deaths in hospitals. More than 200,000 people die due to medical errors in the US each year, and more the 4.8 million worldwide.

During this important meeting, administrators, clinicians, patient safety advocates, family members and other patient safety leaders from across the healthcare ecosystem had an opportunity to share experiences and expertise to help develop solutions to eliminate preventable patient deaths.

The meeting began with a special video message from Dr. Tedros Adhanom Ghebreyesus, Director General of the WHO thanking those who have made a commitment to patient safety and challenging others to make the same commitment to support the WHO in making patient safety a global priority.

“No one should be harmed when seeking healthcare,” said Joe Kiani, PSMF founder. “Even one preventable death is one too many. World Patient Safety Day activates every stakeholder across the healthcare ecosystem to ‘Speak up for patient safety.’ I challenge you to join us and make plans to achieve ZERO.”

During the day, general sessions demonstrated to those in attendance how individuals and organizations have changed policies and processes to eliminate preventable patient deaths.

Breakout sessions focused on solutions for:

    Medication Safety/Opioid Safety (APSS #3 and #4)
    Hand-Off Communications (APSS #6)
    Neonatal Airway Safety (APSS #7 and #8)
    Early Detection and Treatment of Sepsis (APSS #9)
    Systemic Prevention and Resuscitation of In-Hospital Cardiac Arrest (APSS #10)
    Mother/Baby Falls (APSS #11 and #14)
    Embolic Events (APSS #12)
    Person and Family Engagement and Hand Hygiene (APSS #16 and #2)
    Patient Safety Curriculum (APSS #17)
    Post-Operative Delirium in Older Adults (APSS #18)

“The numbers of patients that die each year from preventable hospital errors is just not acceptable, and we know how to lower them,” said David Mayer, PSMF CEO. “Our 34 free Actionable Patient Safety Solutions (APSS) provide specific processes and guidance to help hospitals prevent medical harm. We know how to reduce the number of preventable deaths on our way to eliminating them entirely.”

About Patient Safety Movement Foundation

Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit

View source version on


David Kodama
Cook + Schmid
619-814-2370 x17

Permalink :

The LYCRA Company Announces New Solutions for the Circular Economy Under Its Planet Agenda Sustainability Platform

WILMINGTON, Del. -Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The LYCRA Company announced today that it is amplifying its Planet Agenda sustainability platform with the launch of LYCRA® EcoMade fiber, its first branded elastane made with pre-consumer content. The company also announced plans to convert the majority of COOLMAX® and THERMOLITE® fiber products to include recycled content by the end of 2021. The official launch will take place at Intertextile Shanghai, September 25-27.

 “The Planet Agenda platform focuses on providing insights, technologies, products, and processes that can contribute to a more sustainable industry,” says Jean Hegedus, The LYCRA Company’s sustainability director. “Planet Agenda is built around three interdependent pillars: product sustainability, manufacturing excellence, and corporate responsibility. Through these pillars, we offer a variety of sustainable solutions focused on waste reduction, safe and transparent chemical usage, garment wear life, and sustainable resources.”

The EcoMade family of recycled products now spans the majority of The LYCRA Company’s apparel brands, including LYCRA®, LYCRA® T400®, COOLMAX®, and THERMOLITE® fibers.

Earlier this year, the company announced that LYCRA® 166L fiber, which is used in wovens, has been granted Gold Level Material Health Certification from the Cradle to Cradle Products Innovation Institute. All of The LYCRA Company’s LYCRA® fiber apparel production sites are also certified for OEKO-TEX® Standard 100, in accordance with Appendix 6. A complete list of product certifications can be found online at:

The LYCRA Company will be showcasing many of these innovations at the upcoming Intertextile Show in Shanghai, September 25-27. Guests are invited to visit the LYCRA® brand stand E56 in Hall 4.1, and E55 in Hall 7.2 (Denim), to see the latest sustainable options and discuss opportunities for collaboration.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries, as well as specialty chemicals used in the spandex and polyurethane value chains. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, L by LYCRA®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, TACTEL®, and TERATHANE®. While The LYCRA Company’s name is new, its legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company is focused on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit

LYCRA®, T400®, COOLMAX®, and THERMOLITE® are trademarks of The LYCRA Company.

This press release features multimedia. View the full release here:


Karie Ford
+ 1.302.287.3095

Permalink :

Citi Empowers Middle Office Clients with Flexible Investment Data Delivery

LONDON-Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Citi has upgraded its Investment Book of Record (IBOR) data delivery service to support Middle Office clients operating across multiple trading cycles. The so‑called ‘multi-slot’ IBOR solution can be customised to meet the operational needs of individual clients across their front office locations in various regions, particularly informing start-of-day trading positions and cash forecasts globally.

The enhanced IBOR solution provides clients with positions, traded and settled cash, transactions, instrument master data, foreign exchange rates and cash forecast data driven by regional valuations for listed and OTC assets. The service also includes a historically correct IBOR (HCIBOR) solution which can seamlessly integrate with existing performance and client reporting services.

“The core strength of our offering is the richness of the data, the speed of delivery, and its flexibility to meet clients’ needs, whilst being order management system, custodian and fund accountant agnostic,” said Pervaiz Panjwani, EMEA Head of Custody and Fund Services. “With a comprehensive data model, comprised of over 600 unique data elements including OTC supplemental data, backed up by Citi’s extensive control framework, we can support a wide range of investments and facilitate decision making.”

Citi’s enhanced IBOR data delivery service is now live and available as a standard part of its Middle Office Services. This enhancement coincides with the culmination of multiple years of investment in its middle office platform, a suite of highly automated and integrated capabilities that includes trade processing, asset servicing, OTC valuation and collateral management services, portfolio accounting, and performance and risk reporting.

“As our global clients expand across markets and investment types, they operate in increasingly complex environments,” said Sanjiv Sawhney, Global Head of Custody and Fund Services. “Clients will look to partner with a provider that can solve complex problems, simplify their operations and support their growth.”

With over $21.7 trillion of assets under custody and administration and the industry-leading proprietary network spanning over 60 markets, Citi’s Custody and Funds Services business provides clients with in-depth local market expertise, advanced processing technologies and a wide range of fund services that can be tailored to meet clients’ needs.

About Citi:

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at | Twitter: @Citi | YouTube: | Blog: | Facebook: | LinkedIn:

View source version on


Media Contact:
Francesco Meucci
+44 207 508 0717

Nina Das
+1 212 816 9267

Permalink :

The real and the virtual meet at IBC2019 Awards

LONDON-Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- The IBC2019 Awards saw recognition for the real – in terms of socially responsible projects and charitable bodies – and the virtual, including holograms over 5G and the cutting edge in delivering augmented reality. The two came together in the International Honour for Excellence, presented to Andy Serkis.

A remarkable live actor in theatre, film and television, Serkis is now best known for redefining the art of performance capture. His skills and intensity have created characters as varied as Gollum, King Kong and Tintin’s Captain Haddock: all computer generated; all dependent upon his skills and experience to create the fidelity, the detail, the humanity.

In an on-screen tribute, actor Woody Harrelson, who co-starred in War for the Planet of the Apes, said “Andy is one of the most gifted actors I’ve ever encountered. It blows my mind to see how much he can convey just in his eyes.”

Accepting the award from Naomi Climer, chair of the IBC Council, Andy Serkis said “I’m deeply honoured to be here as part of this eclectic, worldwide community, a community that is quintessentially enabling a reality of the ambitions of someone like myself who seeks to bring characters and stories into existence, to hopefully – in some tiny way – change the world for the better.”

He thanked his family “who have born with two decades of me in Spandex and spots, God bless them”, and concluded with “Thank you IBC for this most incredible award. I am thrilled and I will cherish it always”.

IBC Social Impact Award

IBC introduced two new award categories this year. Competition for the social impact award was so intense that the judges awarded not one but three trophies.

The first went to Turkish broadcaster TRT for its World Citizen programme, and particularly for its Journalism for Juniors initiative. This teaches young people, including those in the country’s large refugee camps, how to take their native social media skills and develop their story-telling abilities.

“J4J is a celebration of global access to media, which is a human right,” said Zia Ahmed Eshanzada, senior campaign specialist at TRT. “We hope to encourage others to create similar programmes.”

Following the devastating Boxing Day tsunami in 2004, the Indian authorities recognised they needed not just to monitor the threat from the sea, but to communicate information and warnings to the people likely to be affected. Gaian Solutions developed Sagar Vani, an omni-channel citizen engagement platform, which received the second of the awards.

“Proper application of technology can ensure that both the ‘haves’ and the ‘have nots’ get access to the same quality of service – especially in terms of life-saving emergency services,” said Gaian CEO Chandra Kotaru.

The third trophy went to Chouette Films, an initiative of the University of London’s School of Oriental and African Studies. This aims to produce academic and informative content with the smallest of environmental footprints.

As Chouette Films says, it aims for “increased impact on humanity with minimal impact on the planet. Recognising environmentally and socially conscious film production is one small step for IBC, but one giant leap for the industry at large – we’re over the moon to be a part of it.”

IBC Young Pioneer Award

The second new category recognised young people making their mark in the industry. The audience heard about seven finalists, all under 30, successful in areas as diverse as interactive video production and business management.

The award, though, went to Vera Bichler. Vera is a graduate of the HBS Broadcast Academy, and is now the first female football director at Austrian national broadcaster ORF.

Accepting the trophy, Vera said “Today I am the first woman in directing for the ORF, but I hope in a few years it is not going to be that huge an issue, because gender wouldn’t matter.”

IBC Innovation Awards

Sail GP took the first of the three IBC Innovation Awards, for Content Creation. This is a new competition for very high speed yachts racing in scenic harbours and coastal regions around the world. Wherever the venue, though, all the feeds are routed back to Timeline Television in England, for live production in three different languages.

From the very many nominations, the jury of international editors and technology consultants produced a shortlist of four for this award: Fox Sports, with technology partners Epic Games and Zero Density for its new augmented reality Nascar studio; Riot Games for remote production of the League of Legends e-sports championship, using Haivision technology; and Vodafone in Romania which used 5G to carry a live hologram from one side of Bucharest to the other, allowing a 10 year old guitar prodigy to play with his favourite band. Dejero, Hawthorn Theatrical, Huawei and Musion 3D were technology partners.

If the award for content creation was for thrilling action on the sea, the IBC2019 Innovation Award for Content Distribution took us beneath the waves. Associated Press, with its technology partners Inmarsat, LiveU and Sonardyne, broadcast live from an untethered submersible at 200 metres, using the Indian Ocean itself as the bearer for optical HD transmission.

Running AP very close for the award was BT Sport, which with the help of EE, Huawei, Mobile Viewpoint and Timeline Television provided coverage of a football match at Wembley Stadium, remotely produced thanks to 5G transmission of the cameras; and COPA90, which with the help of Base Media Cloud developed a tremendously engaging social media platform for the 2018 FIFA World Cup.

Winner of the award for Content Everywhere was India’s ETV Bharat. With technology partners Aveco, Grass Valley, Harmonic, Octopus, Ross Video and VTI is has developed a cross-platform news infrastructure at massive scale – 5000 journalists covering 29 states, and working in 13 languages.

Also shortlisted for the award were Deutsche Telekom (supported by Akamai, Iconic Engine, INVR.SPACE, Magnum Film, MediaKind and Tiled Media) for live 6k, 360˚ VR; and Facebook, which has brought La Liga to the Indian sub-continent on Facebook Watch, with additional technology from Guud and MediaPro.

Special Award

Picking up on the social impact theme, IBC presented a Special Award to 4K 4Charity. At IBC2014, Sam Blackman of Elemental founded a Saturday morning fun run. 4k was the 2014 technology buzz, and 4km seemed like a reasonable target for a run at 7.30 am in the middle of a trade show, and so 4K 4Charity was born.

Sadly, Sam died in 2017, but his charitable legacy lives on. There are now four 4K 4Charity runs a year, and more than a million dollars has been raised for non-profit organisations concerned with increasing equality and driving diversity. Elemental – now AWS Elemental – continues to provide the administrative support, so that 100% of registration fees go to the good causes.

The IBC2019 event was started by soccer star Robin van Persie. It saw 631 registered runners, who were joined by a goat which escaped from the local petting zoo. One of the biggest cheers of the awards ceremony greeted the video which showed the goat beating van Persie over the finish line.

Accepting the award, Laura Barber said “What Sam loved about this run is how efficiently it helped us raise money for non-profits focused on increased equity, as well as letting folks engage in a healthy, unique, fun activity amidst the intensity of tradeshow. IBC is where it all began, and we are honoured to receive this award.”

Best technical paper

This year’s prize for the best technical paper went to researchers from Finland, seeking practical solutions for the delivery of realtime augmented reality content to mobile devices. Sebastian Schwarz of Nokia Technologies accepted the trophy on behalf of his colleague Mika Pesonen and Jani Norminen of Innogiant.

View source version on


Aimee Moore
Marketing Assistant
T +44 (0) 2078324104
F +44 (0) 2078324130

Permalink :

Friday, September 20, 2019

Shiseido Marks the 30th Anniversary of Joint Research in Dermatology

 -Another 6 years of alliance with US Dermatology Laboratory-

TOKYO-Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Shiseido Company, Limited (“Shiseido”) has agreed on Tuesday, September 17, 2019 to extend for a further six years its research alliance with the dermatological laboratory CBRC (Cutaneous Biology Research Center), established by Harvard Medical School Dermatology Research Labs, and Massachusetts General Hospital in Boston, Massachusetts, USA. This new agreement will be effective July 2021 through June 2027.

The CBRC was founded in 1989, and is known as a world-class laboratory in the field of dermatology. Shiseido has been collaborating for 30 years with the CBRC as a pioneer of open innovation pursuing unprecedented research collaboration with external organizations both nationally and internationally. Many of the cutting-edge research results are utilized in our product research and development.

Going forward, to achieve our corporate mission, “BEAUTY INNOVATIONS FOR A BETTER WORLD,” Shiseido will continue joint research with the CBRC and create cutting-edge value through research in dermatology including ultraviolet rays and aging, as well as development of innovative cosmetic products. Furthermore, in addition to research and development, we will also provide consumers with information to maintain healthy skin, such as basic knowledge on UV rays and the impact of photoaging, etc. through seminars and symposiums.

To celebrate the 30th anniversary of the CBRC and new six-year extension of the alliance, three representatives—Shiseido’s President and CEO Masahiko Uotani, Executive Vice President Yoichi Shimatani, and CBRC Director David E. Fisher, MD, PhD—gave comments as follows:

Shiseido’s President and CEO, Masahiko Uotani:
“In our quest to remain vital for the next 100 years and beyond, this year, we at Shiseido created a new corporate mission “BEAUTY INNOVATIONS FOR A BETTER WORLD.” Ongoing efforts to foster innovation is our responsibility and mission to make this world better through the power of beauty. The CBRC is an indispensable and important partner for Shiseido to create unprecedented, first-of-its-kind value and change the lives of people around the world. Let us cling together for the future and challenge for the innovation that surpasses society's expectations.”

Executive Vice President, Yoichi Shimatani:
“It has been 30 years since we began our partnership with the CBRC. We have delivered many outstanding research achievements, more than we had initially imagined, realizing ideal collaboration between laboratories in academia and a company. We will continue to create innovation with the CBRC, a state-of-the-art laboratory that symbolizes our open innovation activities.”

CBRC Director, David E. Fisher:
“The Shiseido-CBRC relationship is a source of immense pride to Dermatology at Mass General Hospital/Harvard Medical School. Close collaboration at the cutting edge of science is the shared mission, and numerous significant discoveries continue to be made through common efforts. We are proud to celebrate 30 years of important discoveries by our scientists working together, and look forward to continued progress in optimizing all aspects of skin health and wellbeing.”

About CBRC
The CBRC is a general research institute for advanced research and development in the field of dermatology established by Harvard Medical School and Massachusetts General Hospital with support from Shiseido in 1989. We started collaborative research 30 years ago and since then we have achieved many remarkable research results in skin and hair science. Many researchers have also been dispatched from Shiseido, contributing to the cultivation of global research talent.

Major joint research achievements between the CBRC and Shiseido in the past 30 years

The world’s first research achievements in skin and hair science.




"Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide"

Through this discovery, provided a lead to elucidate the phenomenon that skin diseases observed in clinical settings are exacerbated by mental stress. This research paper was published in science journal Nature in 1993, and many related research papers were presented.


"Importance of balance between extracellular matrix synthesis and degradation in basement membrane formation"

Clarified the importance of the balance in biosynthesis and degradation of laminin 5 and type VII collagen in basement membrane formation, and the mechanism that promotes the formation. Shiseido won the IFSCC* top award in 2000 for related research.


"Profile of transforming growth factor-beta responses during the murine hair cycle"

Discovered the mechanism of two genes TSC-22 and Smad2 involved in epilation.


"Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression"

Elucidated that the induction of capillaries beneath the epidermis due to UV irradiation causes wrinkles.


"Dedicated epithelial recipient cells determine pigmentation patterns"

Newly found that pigment recipient cells send a signal to pigment cells to determine the pigmentation pattern. This research paper was published in the world-renowned academic journal Cell in 2007.


"Hepatocyte growth factor promotes lymphatic vessel formation and function"

"A Novel Mechanism of Cutaneous Photo-Aging Mediated by the Impairment of Lymphatic Function and the Protective Role of a Lymphatic-promoting Compound”

Discovered that UV-exposed skin deteriorates the function of lymphatic vessels, leading to the creation of wrinkles. Furthermore, developed the drug that suppresses the phenomenon.


“Reduction of oxidative stress in living body by promoting expression of redox-related factors”

Discovered that kaempferol, a kind of polyphenol, and ginkgo biloba, which contains kaempferol, significantly suppress the level of cell damage caused by UV rays. Shiseido and CBRC jointly own the patents (joint applications).


"Ex-vivo demonstration of the disruption of skin homeostasis and the role of extracellular ATP in the reaction"

"Ex-vivo analysis of localized response to environmental stress in human skin"

Discovered that heparanase, one of the factors that promote basement membrane degradation, increases in the epidermis due to external environmental stress such as dryness.

* IFSCC (The International Federation of Societies of Cosmetic Chemists): An international organization dedicated to the development of highly functional and safe cosmetic technology through the world-wide cooperation of cosmetic societies.

View source version on


Ms. June Sato
Shiseido Company, Limited

Permalink :

Larger, healthier, more plentiful — Study proves House Wellness Foods’ Feed LP20® improves stock at the cellular level.

TOKYO -Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Eons ago, the progress of humankind was thrust forward with the development of farming. Today that progress is challenged simultaneously by climatic and socioeconomic forces, and the future hangs in the balance. Our fundamental need is to nourish the world, and the means to achieve that is increased efficiency in agriculture and aquaculture.

To this end, House Wellness Foods has released yet another groundbreaking clinical study showing that its pioneering, immunobiotic-based Feed LP20®, with the primary ingredient, heat-killed Lactobacillus plantarum L-137 (HK L-137), demonstrably increases the farming output, size, and health of genetically-improved farmed tilapia (GIFT), a food with endless potential for feeding diverse populations across the globe. The conclusions of this study could have world-altering impact on the field of aquaculture, and the company will be sharing these at Aquaculture Europe, taking place in Berlin, October 7-10, where one of the study’s directors, Mahmoud A.O. Dawood, will present the group’s findings for the first time.

House researchers, working alongside Vietnam’s Research Institute for Aquaculture No. 2 (RIA2), previously released a study demonstrating the efficacy of Feed LP20® on Nile Tilapia [Oreochromis niloticus], one of the hardiest, most nutrient-rich and commercially viable farmable seafood species available. At issue was the fact that though this species could be farmed in a number of environments, increased consumption accelerated production, which inevitably led to water management issues, forcing a surge in the use of antibiotics, pesticides, and disinfectants. Apart from the twin dangers of seepage into the food chain and giving rise to disease resistance, the fish themselves were subjected to excessive stress, which broke down their immunity and degraded the population.

The current research proves that beyond HK L-137s proved ability to support innate immune functions, warding off destructive cellular activity before its effects necessitate the use of solutions such as antibiotics and antimicrobials, the bacillus actually modulates digestive enzyme activity, blood health, oxidative responses, and growth-related gene expression, significantly improving the crop across all performance parameters — final body weight, weight gain, specific growth rate, and feed efficiency ratio (FBW, WG, SGR, FER). Further, and partly accounting for these dramatic improvements, sampled fish exhibited expanded mucosal thickness and villus length, which promote increased dietary nutrient utilization, as well as significantly increased amylase, lipase and protease activity.

Feed LP20® with HK L-137 proved to modulate blood hematocrit and hemoglobin levels, RBC and WBC counts (P < 0.05), while decreasing total cholesterol and GPT. Additionally, antioxidative enzyme (SOD and CAT) activity was raised greatly (P < 0.05), while MDA levels were lowered. Fish fed HK L-137 also showed enhanced total serum protein and IgM levels.

House Wellness Foods is a pioneer in, and the world’s premier producer of immunobiotic functional foods. Their farming and aquaculture product Feed LP20® containing HK L-137 features the same attributes as their popular, proven consumer product, Immuno LP20®. Notably, high solubility, resistance to breakdown, and unequaled shelf life and stability. The benefits of this approach can produce food that is safer, more nutritious, and importantly, more plentiful, without risking the dangers and depredation associated with antibiotics and disinfectants.

House Wellness Foods immunobiotic-based Feed LP20® offers a solution that is both forward-thinking and prudent, and has benefits that go beyond solving the immediate problem, offering hope for the eventual alleviation of hunger and malnutrition, and their demoralizing and destructive effects. We invite you to join us and discuss the promise of this research and more at Aquaculture Europe in October.

View source version on


Permalink :

Toshiba Memory Holdings Corporation Appoints Lorenzo A. Flores as Vice Chairman

TOKYO-Friday 20 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Toshiba Memory Holdings Corporation, which will officially rebrand as Kioxia Holdings Corporation on October 1, 2019, today announced the appointment of Lorenzo A. Flores as Vice Chairman, effective in November, 2019.

Mr. Flores brings a proven track record of strong executive leadership to the company with extensive financial experience in the technology industry. Mr. Flores will work closely with the executive management team to help lead global business expansion.

Mr. Flores previously spent eleven years at Xilinx Inc., where he served as Chief Financial Officer since May of 2016, and Executive Vice President since February of 2018. In addition to his finance roles, Mr. Flores had responsibility for the company's Information Technology function. During his tenure as Chief Financial Officer, Xilinx established all-time highs for Revenue, Earnings Per Share, and Operating Cash Flow. Prior to joining Xilinx, Mr. Flores served as Assistant Vice President of Financial Planning and Analysis at Cognizant Technology Solutions. He also spent ten years at Intel Corporation, serving in a variety of positions including Controller for the Intel architecture’s CPUs Group.

Mr. Flores holds bachelor’s degrees in Civil Engineering and Management Science from the Massachusetts Institute of Technology, and a Master of Business Administration from University of California, Los Angeles.

“We are thrilled that Lorenzo is joining us in this crucial leadership role at the beginning of Kioxia’s history,” said Stacy J. Smith, Executive Chairman of Toshiba Memory Holdings Corporation. “With Lorenzo’s excellent experience and knowledge of the semiconductor industry, he is a great addition to an already deep and experienced leadership team. There is no doubt he is the perfect person to help lead our company through its next phase of growth as Kioxia.”

“I am excited to take on this position and honored to join the team as it begins its exciting new journey as Kioxia,” said Mr. Flores. “Toshiba Memory has always been a leader in the memory industry, and Kioxia is well positioned to lead us into a new era of memory.”

About Toshiba Memory
Toshiba Memory Group, a world leader in memory solutions, is dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Toshiba Memory pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers. Toshiba Memory will officially change its name to Kioxia on October 1, 2019. For more information on Toshiba Memory, please visit

View source version on


For More Information
Sam Ghirardello (phone: +81-3-5427-7396,
Masahiko Oshiro(phone: +81-3-5427-7384,
Weber Shandwick (Tokyo)

Public Relations
Toshiba Memory Holdings Corporation

Mary Kay Reveals Breakthrough Anti-Gravity Findings at the 49th European Society for Dermatological Research Meeting

DALLAS-Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Mary Kay Inc., a leader in skin care innovation, continues its decades-long commitment to skin science by sharing its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held on September 18-21 in Bordeaux, France.

By uniting the finest specialists of European dermatology under the umbrella theme “Connecting Skin Science and Health,” the 49th ESDR meeting provides a unique opportunity for Mary Kay to share its latest technological advances and breakthroughs on skin health.

The appearance of slackened, sagging skin tends to become prevalent in the fourth or fifth decade of life regardless of lifestyle or environmental exposure. The constant effect of gravity over time contributes to the emergence of prominent nasolabial folds and sagging skin along the jawline and neck.

“As sagging skin is a consumer concern, we developed a treatment product specifically targeted to lift sagging skin,” insists Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay Inc. “Our scientists tested hundreds of materials on human skin cells to identify the most effective combination of ingredients that help promote natural hyaluronic acid and collagen, the two factors that are reduced in slackened skin. A unique peptide and meristem cells from the Centella asiatica plant stood out in terms of efficacy. That’s why we selected them for use in a cosmetic serum. The serum efficacy has been verified in our labs and by women themselves on their skin in clinical tests.* This is the science behind our TimeWise Repair® Volu-Firm® Lifting Serum,” explains Dr. Gildea.

Led by Dr. Gildea, Mary Kay’s Research and Development team comprises of distinguished scientists holding doctorates and other advanced degrees across multiple disciplines: skin biology, cell biology, chemistry, biochemistry and more. This team of scientists are committed to discovering the trends and technologies that enable the company to create irresistible products that deliver benefits to consumers.

Every year, Mary Kay conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality, and performance. Mary Kay holds more than 1,500 patents for products, technologies, and packaging designs in its global portfolio. Last year, the company opened a more than $100 million state-of-the-art manufacturing and R&D facility in Lewisville, Texas.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at

*In a clinical study, 45 women applied the cosmetic serum to the face twice daily for 12 weeks. Skin firmness and lifting attributes showed statistically significant improvements after 4, 8 and 12 weeks of product use relative to baseline. At least 98% of subjects showed improvements in multiple parameters for lifting along the contours of their face (cheek/jawline).

This press release features multimedia. View the full release here:


Mary Kay Inc. Corporate Communications
972.687.5332 or

Permalink :

Upfield Announces Strategic Partnership with Starling (Earthworm and Airbus) to Leverage Satellite Data to Help Validate Their Commitment on No Deforestation

Upfield Meets Target to Source 100% Physically Certified Sustainable Palm Oil

Ahead of December 2019 Target

AMSTERDAM -Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Today, Upfield, a leading producer of plant-based products, announced partnership with Starling to ensure their ongoing support for Upfield’s vision for a “Better Plant Based Future” drives innovation in ingredient sourcing that protect the world’s precious ecosystems and preserves our planet for future generations.

In response to climate change and the devastating impact of deforestation, Upfield is committed to responsibly sourcing ingredients, paying particular attention to palm oil, soybean oil and paper, vetting partners to verify compliance with Upfield policies and maintaining transparency by publishing details of product ingredient sources. Upfield is committed to driving industry transformation and ensuring that deforestation doesn’t take place within their supply chain.

At the beginning of the year Upfield committed to source 100% of its palm oil from physically certified, sustainable sources by December 2019 and today can announce that they have achieved this target. All the palm oil Upfield directly purchases is now 100% physically certified to RPSO standards.

“This is an important step in delivering on our palm oil policy commitments,” said Sally Smith, Head of Sustainability, “ensuring we source our directly purchased ingredients sustainably and responsibly, particularly where there is a risk of deforestation, is a priority for Upfield. There continues to be more to do.”

Upfield sources both mass balance and segregated certified palm oil and will continue to work with suppliers and farmers to increase the proportion of segregated palm oil used in its products.

Upfield also shares the concerns about the production of soy products and is working toward full transparency, collaborating with community leaders and expert third parties. Ninety-five percent of Upfield’s soybean oil is grown in the United States and Canada and is compliant with local environmental regulations. The remaining five percent is sourced from Europe and Brazil, in compliance with the Amazon Basin Soy Moratorium Zone.

Additionally, today Upfield is announcing their partnership with Starling to use their innovative satellite monitoring technology platform to further support efforts in eradicating deforestation from their supply chain. Starling, created by Airbus and Earthworm, uses high resolution imagery and radar data to monitor land cover changes.

By mapping the location of mills within the supply chain, Upfield will be able to see where deforestation continues to occur. Upfield will be piloting the system initially in Indonesia where 50% of its palm oil and 70% of the high risks mills in their supply chain are located. In 2020 they will extend its use to cover their global palm oil supply chain. And finally, they will use the information to verify compliance and to help address deforestation risks with their suppliers.

Transparency is essential in ensuring sustainable supply chains and Upfield is committed to monitor, verify and act on the insights that Starling will provide. “Only by being equipped with information about deforestation and supply chains are companies able to take proactive action to tackle deforestation and evidence progress. That is what will eventually allow consumers and investors to really see which companies are truly walking the talk,” said Bastien Sachet, CEO of Earthworm Foundation.


At Upfield, we make people healthier and happier with great tasting, plant-based nutrition products that are better for the planet. As a global plant-based company, Upfield is the #1 producer of plant-based spreads with more than 60 brands, including iconic brands Flora, Rama, Blue Band, Proactive, Becel, I Can’t Believe It’s Not Butter and Country Crock. With headquarters in Amsterdam, we sell our products in over 95 countries and have 17 manufacturing sites throughout the world. The company employs over 3500 Associates. Since 1871, we have been the authority in the spreads category which gives us unmatched experience, know-how and inspiration. We are focused on leading in this new era focused on delivering healthier products that are great tasting and have superior quality and helps us deliver on our mission to create “Better Plant-based Future.” For more information, please visit our website at

View source version on


Suzanne Lyons

Bridget Health
011 44 7734 681458

Permalink :

Schlumberger Announces Tender Offer for Any and All of Schlumberger Holdings Corporation’s Outstanding 3.000% Senior Notes Due 2020 and 3.625% Senior Notes Due 2022

HOUSTON-Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE) -- Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of Schlumberger (“SHC”), has commenced a cash tender offer for any and all of its outstanding (a) 3.000% Senior Notes due 2020 (the "2020 Notes") and (b) 3.625% Senior Notes due 2022 (the "2022 Notes,” and together with the 2020 Notes, the "Notes"), on the terms and subject to the conditions set forth in the Offer to Purchase, dated the date hereof (as may be amended or supplemented from time to time, the "Offer to Purchase") and the related Notice of Guaranteed Delivery attached to the Offer to Purchase (as may be amended or supplemented from time to time, the "Notice of Guaranteed Delivery"). As of September 18, 2019, there were $1,198,732,000 aggregate principal amount of the 2020 Notes outstanding and $616,522,000 aggregate principal amount of the 2022 Notes outstanding. The tender offer is referred to herein as the "Offer." The Offer to Purchase and the Notice of Guaranteed Delivery are referred to herein collectively as the "Offer Documents."

Certain information regarding the Notes and the pricing for the Offer is set forth in the table below.

Title of Security
CUSIP Numbers
Principal Amount
U.S. Treasury
Reference Security
Reference Page
Fixed Spread
3.000% Senior Notes
due 2020
806851AC5 /
1.875% U.S. Treasury
Notes due December 15, 2020
25 bps
3.625% Senior Notes
due 2022
806851AE1 /
1.500% U.S. Treasury
Notes due September 15, 2022
35 bps

Holders must validly tender (and not validly withdraw) their Notes, or deliver a properly completed and duly executed Notice of Guaranteed Delivery for their Notes, at or before the Expiration Time (as defined below) in order to be eligible to receive the applicable Tender Offer Consideration (as defined below). In addition, holders whose Notes are purchased in the Offer will receive accrued and unpaid interest from the last interest payment date to, but not including, the Settlement Date (as defined in the Offer to Purchase) for the applicable Notes. SHC expects the Settlement Date to occur on September 27, 2019, the third business day after the Expiration Time.

The Offer will expire at 5:00 p.m., New York City time, on September 24, 2019 (such time and date, as it may be extended, the "Expiration Time"), unless extended or earlier terminated by SHC. The Notes tendered may be withdrawn at any time at or before the Expiration Time by following the procedures described in the Offer to Purchase.

SHC's obligation to accept for purchase and to pay for Notes validly tendered and not validly withdrawn pursuant to the Offer is subject to the satisfaction or waiver, in SHC's discretion, of certain conditions, which are more fully described in the Offer to Purchase. The complete terms and conditions of the Offer are set forth in the Offer Documents. Holders of the Notes are urged to read the Offer Documents carefully.

The applicable "Tender Offer Consideration" for each $1,000 principal amount of Notes validly tendered and not validly withdrawn and accepted for purchase pursuant to the Offer will be determined in the manner described in the Offer Documents by reference to the applicable fixed spread for such Notes specified in the table above plus the yield based on the bid-side price of the applicable U.S. Treasury Reference Security specified in the table above at 2:00 p.m., New York City time, on September 24, 2019, unless extended.

SHC has retained D.F. King & Co., Inc. ("D.F. King") as the tender agent and information agent for the Offer. SHC has retained Goldman Sachs & Co. LLC as the dealer manager for the Offer.

Holders who would like additional copies of the Offer Documents may call or email D.F. King at (866) 530-8635. Copies of the Offer to Purchase and the Notice of Guaranteed Delivery are also available at the following website: Questions regarding the terms of the Offer should be directed to Goldman Sachs & Co. LLC at 200 West Street, New York, NY 10282, telephone (800) 828-3182 (toll-free), (212) 902-6351 (collect), Attn: Liability Management.

This press release shall not constitute an offer to buy or a solicitation of an offer to sell any Notes. The Offer is being made solely pursuant to the Offer Documents. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offer to be made by a licensed broker or dealer, the Offer will be deemed to be made on behalf of SHC by Goldman Sachs & Co. LLC or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “believe,” “plan,” “estimate,” “intend,” “anticipate,” “should,” “could,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements regarding the terms and timing for completion of the Offer, including the acceptance for purchase of any Notes validly tendered and the expected Expiration Time and Settlement Date thereof, and the consideration of the Offer. Schlumberger and SHC cannot give any assurance that such statements will prove correct. These statements are subject to, among other things, the risks and uncertainties detailed in Schlumberger's most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the Securities and Exchange Commission. Actual outcomes may vary materially from those reflected in Schlumberger's forward-looking statements. The forward-looking statements speak only as of the date made, and Schlumberger disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

View source version on


Simon Farrant – Vice President of Investor Relations, Schlumberger Limited
Joy V. Domingo – Director of Investor Relations, Schlumberger Limited
Office +1 (713) 375-3535

Permalink :

CosmeSurge opens Anti-aging unit, host first session on diabesity and how to combat it

The event will provide a platform to trigger discussions regarding diabetes, obesity and its side effects

Dubai, United Arab Emirates, -Thursday 19 September 2019 [ AETOS Wire ]

CosmeSurge, one of the region’s most trusted brands for cosmetic and aesthetic procedures will soon be opening an antiaging unit dedicated to maintaining and promoting the well-being, health and aesthetic appearance of patients based on three main pillars which are integrative medicine, wellbeing of men & women and aesthetic anti-aging.

The unit aims to address all these factors and in an attempt to further focus on an individual’s overall wellbeing, will be hosting the ‘Dubai 4 Week Diabesity Cure,’ to shed light on weight and diabetes management and the lifestyle to be adapted to better one’s health.

NMC Health’s Chief Operating Officer Michael Davis said “We are excited to launch our new unit focusing on Anti-aging and Integrative Medicine, overseen by healthcare professionals who will focus on helping individuals who seek advice on how to successfully combat factors that lead to aging; particularly an unhealthy or sedentary lifestyle. This is something we at CosmeSurge and NMC are passionate about and I’m proud we are taking this first step forward.”

The keynote speaker for the event will be Dr Graham Simpson, author and creator of the ‘4 Week Diabesity cure,’ who has dedicated his life’s work to researching and understanding the major cause of the disease and developing a cure for them. His research has helped him develop an “INTEGRAL,” model that recognises the eight root causes of diabetes. The model has been implemented using AI, real-time mobile technology, medically supervised, with trained doctors and health coaches to guide clients through the program. His approach also moves clients away from reactive disease medicine towards proactive (4P) Medicine i.e. personalised, predictive, preventive and participatory focused activities for extending both the clients health-span and lifespan.

Overtime it has been observed that the leading cause of diabesity is the diet adopted by most individuals which is predominately insulin resistant, that involves consuming processed foods loaded with excess sugar, grains and adulterated vegetable oils.

“With increase in insulin levels, the tendency to consume more food increases, thus increasing fat around the stomach, causing inflammation and thus cause other diseases to trigger. Approximately 80 percent of all diseases worldwide, be it heart disease, cancer, stroke, fatty liver, Alzheimer’s and kidney diseases are due to this insulin resistance and need to be treated before they turn fatal,” said Dr Simpson.

Dr Simpson along with other experts in the field spoke to the attendees about how to reverse the disease in a few months, which includes supplementing it with a well-formulated keto diet, intermittent fasting, along with some continuous glucose monitoring (CGM).

About CosmeSurge

Founded in 2002, CosmeSurge is one of the region’s most trusted brands for cosmetic procedures. CosmeSurge offers modern, high quality dermatology and plastic surgery treatments, and dentistry, at fourteen clinics in the GCC.

The clinics are staffed by highly qualified plastic surgeons, dermatologists and aestheticians.

At its state-of-the-art facilities, CosmeSurge provides the highest level of clinical care and service and the full range of cosmetic and dermatology services, with over sixty cosmetic treatments for different areas of the body.

CosmeSurge’s clinics in the UAE are in Dubai, Sharjah, Abu Dhabi, Al Ain, Ras Al Khaimah, Ruwais and Fujairah. CosmeSurge also has a clinic in Muscat, Oman, and one on London’s Harley Street; and it is forging partnerships with leading experts in Los Angeles and other overseas cities.

CosmeSurge is a part of NMC Health Plc. - the largest private sector healthcare provider in the region and the 3rd largest globally. With a worldwide network of over 200 healthcare facilities, NMC has earned the trust of millions and continues to serve communities across 19 countries with its bench-strength comprising of 2000 doctors and 20000 other staff members.


SAHARA Communications

Farah Al Obaidi, Head of Media Relations, +97143298996, +971503323158 /

Permalink :

Thursday, September 19, 2019

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

INGELHEIM, Germany & INDIANAPOLIS, US.-Thursday 19 September 2019 [ AETOS Wire ]

Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1
Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.1
This analysis suggests that, independent of the number of risk factor goals achieved, empagliflozin demonstrated cardiovascular benefits (risk reduction in cardiovascular death, hospitalisation for heart failure and 3P-MACE) in patients with type 2 diabetes and cardiovascular disease that are consistent with primary outcomes from the EMPA-REG OUTCOME® trial.
(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. Results suggest that the risk reduction in cardiovascular events, including cardiovascular death and hospitalisation for heart failure, seen with empagliflozin in the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease, were not affected by the number of controlled cardiovascular risk factors.1

This press release features multimedia. View the full release here:

“Reducing cardiovascular risk in people with type 2 diabetes can be challenging, particularly in those with uncontrolled cardiovascular risk factors, such as blood sugar levels and blood pressure,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “It is therefore encouraging to see these findings from the EMPA-REG OUTCOME® trial in which empagliflozin was shown to improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular disease, irrespective of whether cardiovascular risk factors were controlled.”

In this post-hoc analysis, the cardiovascular benefits of empagliflozin – including risk reduction for cardiovascular death and hospitalisation for heart failure – were investigated in subgroups of people with type 2 diabetes and established cardiovascular disease based on their cardiovascular risk factor goals. These cardiovascular risk factor goals were: blood sugar levels; cholesterol levels or statin use; blood pressure; presence of albumin in the urine; use of blood pressure medication; use of aspirin; and smoking status.1

In the EMPA-REG OUTCOME® trial, empagliflozin provided a 38 percent reduction in the risk of cardiovascular death (HR 0.62; 95% CI 0.49-0.77), a 35 percent reduction in the risk of hospitalisation for heart failure (HR 0.65; 95% CI 0.50-0.85) and a 14 percent reduction in the risk of 3P-MACE (HR 0.86; 95% CI 0.74-0.99), and this post-hoc analysis demonstrates that these cardiovascular benefits were not affected by the number of risk factor goals achieved.1

“Approximately half of all deaths in people with type 2 diabetes are caused by cardiovascular disease. Therefore, ensuring both patients and healthcare professionals understand the importance of cardioprotection remains an urgent priority,” said Sherry Martin, MD, Vice President, Global Medical Affairs, Lilly. “We are pleased to see that these results demonstrate that empagliflozin can help to address this unmet need by offering benefits to people with type 2 diabetes and cardiovascular disease across the spectrum of cardiovascular risk.”

Recent updates to more than 60 treatment guidelines worldwide now include findings from the EMPA-REG OUTCOME trial® as part of their endorsement of treatments with proven cardiovascular benefits for people with type 2 diabetes and established cardiovascular disease.2 Specifically, in the new 2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease – developed in collaboration with EASD – and an Expert Consensus Decision Pathway issued by the American College of Cardiology in 2018, empagliflozin is the recommended SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.3,4

About EMPA-REG OUTCOME® (NCT01131676)5
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The overall safety profile of empagliflozin was consistent with that of previous trials.

About Diabetes and Cardiovascular Disease
More than 425 million people worldwide have diabetes, of which over 212 million are estimated to be undiagnosed.6 By 2045, the number of people with diabetes is expected to rise to 629 million people worldwide.5 Type 2 diabetes is the most common form of diabetes, responsible for around 90 percent of diabetes cases in high-income countries. Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin. 5

Due to complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, cardiovascular disease is a major complication and the leading cause of death associated with diabetes.7,8 People with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes. 7 In 2017, diabetes caused four million deaths worldwide, with cardiovascular disease as the leading cause.5 Approximately 50 percent of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease.9,10

Having a history of diabetes at age 60 can shorten a person’s life span by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke by age 60 can shorten a person’s life span by as much as 12 years compared with someone without these conditions.11

Worldwide, more than 60 guidelines have been updated to endorse type 2 diabetes agents with proven cardiovascular benefits since 2016, including a Consensus Report initiated by the American Diabetes Association® and European Association for the Study of Diabetes, recommending that, in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, SGLT2 inhibitors (such as empagliflozin) or GLP1 receptor agonists with proven cardiovascular benefits are recommended as part of glycaemic management.2,12

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.13,14,15

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

View source version on

Dr Petra Kienle
Product Communication Manager
Boehringer Ingelheim
Phone: +49 (6132) 77 143877

Stephan Thalen
Global Business Communications
Lilly Diabetes
Phone: +1 (317) 276 8304

Permalink :

Innovid Bolsters Omni-channel Advertising Offering With Acquisition of Herolens

Deal Expands Innovid’s Independent Omni-channel Advertising Platform for Delivery, Personalization, and Measurement To Include Display

NEW YORK -Thursday 19 September 2019 [ AETOS Wire ]

(BUSINESS WIRE)-- Innovid, the only independent omni-channel advertising and analytics platform built for television, today announced the acquisition of Herolens, an international advertising software company with expertise in display creative optimization technology. The acquisition expands Innovid’s existing global ad serving, dynamic creative personalization, and advanced measurement capabilities to include display formats alongside the company’s award-winning TV, video, and social solutions.

Herolens is the leading creative management platform headquartered in Latin America, focused on delivering data-driven, dynamic and personalized creative on behalf of brands such as Coke, Renault, and Mercado Libre. Known for their flexible self-service, hybrid and full-service models, clients use Herolens as a central hub for digital asset management and dynamic creative customization, as well as display ad serving.

“We’ve heard first-hand from our clients, the world’s largest TV spenders, the need to leverage data to connect all channels, including TV,” said Zvika Netter, CEO and Co-Founder, Innovid. “We continue to lead with the most advanced TV and video capabilities in the market, while also providing brands their desired goal of a single stack via adding support for display ads. With TV at the center, brands can now go deep and wide seamlessly managing connected experiences across TV video, social, mobile and display to improve customer engagement and business outcomes.”

Netter continued, “As brands look to own their data for a single view of the consumer and seek a global independent alternative to the single stack solutions provided by the duopoly of Google and Amazon, Innovid is the only leading alternative for large TV advertisers because of the depth of our offering in TV and the breadth of our offering that is now omni-channel.”

“We were impressed that the largest global brands have chosen Innovid for their video expertise, their first-to-market interactive and data-driven television formats, accredited measurement in OTT and dynamic capabilities across social platforms.” said Alan Karpovsky, Co-CEO, Herolens and selected by Forbes 30 under 30. “Joining the Innovid team will allow us to bring our display expertise to their global customers.”

A profitable company, Herolens built a strong product and engineering team which constitutes almost all of their 40 employees. They, along with the Herolens leadership team including co-founders Alan Karpovsky, Cristian Pereyra, and José Galindo will join the Innovid team. Innovid will continue to operate their office in Buenos Aires which will function as Innovid’s LATAM HQ with representatives in both Mexico and Columbia.

“We’re eager to be a core component of this omni-channel solution, and excited to join this award winning company,” said José Galindo, Co-Founder, Herolens. “From their leading innovation in connected TV to their consistent recognition as a best place to work, Innovid has a culture and commitment to excellence that resonated with us.”

About Innovid

Innovid is the only independent omni-channel advertising and analytics platform built for television. We use data to enable the personalization, delivery, and measurement of ads across the widest breadth of digitally enabled channels in the market including TV, video, display, social, and OOH. Innovid serves a global client base of brands, agencies, and publishers through over twelve offices across the Americas, Europe, and Asia Pacific.

View source version on

Press contact: (FOR MEDIA ONLY)
Meghan Heide

Permalink :